Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer
A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.
Source: onclive.com
Stay updated with breaking news from Penelope B. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.